These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 35967378)
1. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Torres JB; Roodselaar J; Sealey M; Ziehn M; Bigaud M; Kneuer R; Leppert D; Weckbecker G; Cornelissen B; Anthony DC Front Immunol; 2022; 13():814064. PubMed ID: 35967378 [TBL] [Abstract][Full Text] [Related]
2. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment. Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172 [TBL] [Abstract][Full Text] [Related]
4. Ofatumumab for relapsing forms of multiple sclerosis. Gajofatto A; Orlandi R Drugs Today (Barc); 2022 Jan; 58(1):9-21. PubMed ID: 35107090 [TBL] [Abstract][Full Text] [Related]
5. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. Robak T; Robak E BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841 [TBL] [Abstract][Full Text] [Related]
6. Efficient Distribution of a Novel Zirconium-89 Labeled Anti-cd20 Antibody Following Subcutaneous and Intravenous Administration in Control and Experimental Autoimmune Encephalomyelitis-Variant Mice. Migotto MA; Mardon K; Orian J; Weckbecker G; Kneuer R; Bhalla R; Reutens DC Front Immunol; 2019; 10():2437. PubMed ID: 31681317 [No Abstract] [Full Text] [Related]
7. Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys. Theil D; Smith P; Huck C; Gilbart Y; Kakarieka A; Leppert D; Rauld C; Schmid C; Baumgartner R; Stuber N; Cordoba F; Dubost V; Darribat K; Jivkov M; Frieauff W; Kneuer R; Stoeckli M; Reinker S; Mansfield K; Carballido JM; Couttet P; Weckbecker G Front Immunol; 2019; 10():1340. PubMed ID: 31281311 [TBL] [Abstract][Full Text] [Related]
9. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis. Cotchett KR; Dittel BN; Obeidat AZ Mult Scler Relat Disord; 2021 Apr; 49():102787. PubMed ID: 33516134 [TBL] [Abstract][Full Text] [Related]
11. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis. Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716 [TBL] [Abstract][Full Text] [Related]
12. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player]. Pukoli D; Vécsei L Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344 [TBL] [Abstract][Full Text] [Related]
13. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues. Frisch ES; Pretzsch R; Weber MS Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738 [TBL] [Abstract][Full Text] [Related]
14. Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system. Scavone C; Anatriello A; Baccari I; Cantone A; Di Giulio Cesare D; Bernardi FF; Moreggia O; Liguori V; Andreone V; Maniscalco GT; Capuano A Front Neurol; 2024; 15():1383910. PubMed ID: 38994488 [TBL] [Abstract][Full Text] [Related]
15. B cell depletion in the treatment of multiple sclerosis. Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators. Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538 [TBL] [Abstract][Full Text] [Related]
17. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders. Kaegi C; Wuest B; Crowley C; Boyman O Front Immunol; 2021; 12():788830. PubMed ID: 35185862 [TBL] [Abstract][Full Text] [Related]
18. Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis. von Essen MR; Hansen RH; Højgaard C; Ammitzbøll C; Wiendl H; Sellebjerg F Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35672145 [TBL] [Abstract][Full Text] [Related]
19. Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report. Mariottini A; Barilaro A; Lotti A; Marra F; Massacesi L Front Neurol; 2024; 15():1363493. PubMed ID: 38487332 [TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab. Florou D; Katsara M; Feehan J; Dardiotis E; Apostolopoulos V Brain Sci; 2020 Oct; 10(10):. PubMed ID: 33092190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]